文献速递肿瘤 PET/CT放射性药物与辐射防护

FDG PET肝脏弥漫性摄取减低与癌症恶病质及生存期缩短相关

Diffusely Decreased Liver Uptake on FDG PET and Cancer-Associated Cachexia With Reduced Survival.
PubMed 文献 · Clin Nucl Med · 2019-01-01

OBJECTIVES: We investigated clinical characteristics of patients with extremely increased or decreased physiologic F-FDG uptake of the liver and their prognosis.…

要点

  • 肝脏FDG摄取极低(SUVmean≤1.78)提示癌症恶病质可能。
  • 摄取极低组中36.1%符合恶病质诊断,伴存活恶性病灶时比例增至52.6%。
  • 肝脏FDG摄取极低者总生存期显著缩短,中位33个月。

核心结论

  • 肝脏FDG摄取极度减低的癌症患者很可能存在癌症恶病质,且总生存期更低。

研究设计与样本

  • 在肝右叶设置直径3 cm的球形感兴趣区计算SUVmean。
  • 比较对照组(n=30)、肝脏摄取极高组(HG,n=36)和极低组(LG,n=36)的临床资料与总生存期。

主要发现

  • HG组(SUVmean≥3.04)的体重和体质指数显著高于对照组。
  • LG组(SUVmean≤1.78)存在贫血、肝功能受损、全身炎症和营养不良状态。
  • LG组中36.1%符合恶病质诊断标准,伴存活和/或复发恶性病灶者恶病质比例增加52.6%。
  • LG组中位总生存期33个月,显著差于对照组和HG组。

关键数值与推荐

  • 肝脏摄取极高定义为SUVmean>97.5th百分位,极低定义为SUVmean<2.5th百分位。
  • HG组SUVmean≥3.04,LG组SUVmean≤1.78。

临床怎么用

  • 阅读FDG PET/CT时关注肝脏弥漫性摄取减低,警惕癌症恶病质并评估营养与炎症状态。
  • 肝脏FDG摄取极低可能提示预后不良,可辅助生存风险评估。

局限性

  • 回顾性研究设计。
  • 对照组和极值组样本量较小(各36例或30例)。
  • 单中心数据,结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We investigated clinical characteristics of patients with extremely increased or decreased physiologic F-FDG uptake of the liver and their prognosis. METHODS: One thousand four hundred eighty-seven PET/CT scans of patients with known or suspected malignancy were retrospectively analyzed. A spherical volume of interest (3 cm in diameter) was set on the right lobe of the liver to calculate the SUVmean. Scans with extremely high (SUVmean >97.5th percentile) and low (SUVmean <2.5th percentile) FDG uptake in the liver were evaluated. Physical and laboratory data among a control group (n = 30), the extremely high liver uptake group (HG, n = 36), and the extremely low liver uptake group (LG, n = 36) were compared. Overall survival (OS) of the 3 groups was also compared. RESULTS: Body weight and body mass index in the HG (SUVmean ≥3.04) were significantly higher than those in the control group. The LG cases (SUVmean ≤1.78) had anemia, impaired liver function, and systemic inflammation. They were also in a poor nutritional state. The characteristics of LG cases had many things in common with those of cachectic patients. Indeed, 36.1% of LG cases met the diagnostic criteria for cachexia. Moreover, in LG cases with viable and/or recurrent malignant lesions on FDG PET, the proportion of cachexia increased by 52.6%. The OS of LG cases (median, 33 months) was significantly worse than that of controls and HG cases. CONCLUSIONS: Our data indicate that cancer patients with extremely decreased liver FDG uptake were likely to have cancer cachexia and a lower OS.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nakamoto R, Okuyama C, Ishizu K, et al. Diffusely Decreased Liver Uptake on FDG PET and Cancer-Associated Cachexia With Reduced Survival. Clin Nucl Med. 2019. PMID: 31274609. doi:10.1097/RLU.0000000000002658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。